Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
29807757
DOI
10.1016/j.jstrokecerebrovasdis.2018.05.004
PII: S1052-3057(18)30222-2
Knihovny.cz E-zdroje
- Klíčová slova
- Acute ischemic stroke, anticoagulation, antidote, dabigatran, intravenous thrombolysis, reversal,
- MeSH
- antidota škodlivé účinky terapeutické užití MeSH
- antikoagulancia škodlivé účinky terapeutické užití MeSH
- cerebrální krvácení etiologie MeSH
- cévní mozková příhoda farmakoterapie mortalita MeSH
- dabigatran škodlivé účinky terapeutické užití MeSH
- fibrinolytika aplikace a dávkování škodlivé účinky MeSH
- humanizované monoklonální protilátky škodlivé účinky terapeutické užití MeSH
- intravenózní podání MeSH
- ischemie mozku farmakoterapie mortalita MeSH
- lidé MeSH
- rekombinantní proteiny aplikace a dávkování škodlivé účinky MeSH
- retrospektivní studie MeSH
- senioři MeSH
- tkáňový aktivátor plazminogenu aplikace a dávkování škodlivé účinky MeSH
- trombolytická terapie * škodlivé účinky MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antidota MeSH
- antikoagulancia MeSH
- dabigatran MeSH
- fibrinolytika MeSH
- humanizované monoklonální protilátky MeSH
- idarucizumab MeSH Prohlížeč
- rekombinantní proteiny MeSH
- tkáňový aktivátor plazminogenu MeSH
BACKGROUND: Intravenous thrombolysis (IVT) is contraindicated in patients with acute ischemic stroke (AIS) using oral anticoagulants. A specific human monoclonal antibody was introduced to reverse immediately the anticoagulation effect of the direct inhibitor of thrombin, dabigatran. Until now, mostly individual cases presenting with successful IVT after a reversal of dabigatran anticoagulation in patients with AIS were published. Thus, we aimed to report real-world data from clinical practice. METHODS: Patients with AIS on dabigatran treated with IVT after antidote reversal were enrolled in the retrospective nationwide study. Neurological deficit was scored using the National Institutes of Health Stroke Scale (NIHSS) and 90-day clinical outcome using modified Rankin scale (mRS) with a score 0-2 for a good outcome. Intracerebral hemorrhage (ICH) was defined as a presence of any sign of bleeding on control imaging after IVT, and symptomatic intracerebral hemorrhage (SICH) was assessed according to the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) criteria. RESULTS: In total, 13 patients (7 men, mean age 70.0 ± 9.1 years) with a median NIHSS admission score of 7 points were analyzed. Of these patients, 61.5% used 2 × 150 mg of dabigatran daily. Antidote was administrated 427 ± 235 minutes after the last intake of dabigatran, with a mean activated prothrombin time of 38.1 ± 27.8 seconds and a mean thrombin time of 72.2 ± 56.1 seconds. Of the 13 patients, 2 had ICH and 1 had SICH, and no other bleeding complications were observed after IVT. Of the total number of patients, 76.9% had a good 3-month clinical outcome and 3 patients (23.1%) died. Recurrent ischemic stroke occurred in 2 patients (15.4%). CONCLUSION: The data presented in the study support the safety and efficacy of IVT after the reversal of the anticoagulation effect of dabigatran with antidote in a real-world clinical practice.
Citace poskytuje Crossref.org
Effect of Apixaban Pretreatment on Alteplase-Induced Thrombolysis: An In Vitro Study
